Vaccinia virus protein B18R inhibits the activity and cellular binding of the novel type interferon-δ

被引:9
|
作者
Vancová, I
La Bonnardiere, C
Kontsek, P [1 ]
机构
[1] Slovak Acad Sci, Inst Virol, Bratislava 84246, Slovakia
[2] INRA, Lab Virol & Immunol Mol, F-78350 Jouy En Josas, France
来源
关键词
D O I
10.1099/0022-1317-79-7-1647
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The soluble vaccinia virus-encoded protein B18R inhibits the antiviral activity and cellular binding of the type I interferons (IFN)-alpha, -beta and -omega of different mammalian species. Recently, a novel type I IFN was detected in pigs and classified as a member of a distinct IFN family designated IFN-delta. Our study aimed to determine if the structural properties of this shortest(149 residues long) type I IFN allow its interaction with the type I IFN-binding protein B18R. Experiments using bovine (MDBK) cells demonstrated that B18R neutralized the antiviral activity of porcine IFN-delta with high efficiency. Preincubation of B18R with radiolabelled IFN-delta specifically inhibited binding of IFN to bovine cells. These data indicate that the overall conformation of the novel IFN-delta might be similar to that of other type I IFNs.
引用
收藏
页码:1647 / 1649
页数:3
相关论文
共 50 条
  • [1] Neutralization activity of the vaccinia virus B18R protein against the human interferon alpha protein family
    Jubin, Ronald G.
    Carroll, Matthew
    Pestka, Sidney
    CYTOKINE, 2010, 52 (1-2) : 89 - 89
  • [2] VACCINIA VIRUS B18R GENE ENCODES A TYPE-I INTERFERON-BINDING PROTEIN THAT BLOCKS INTERFERON-ALPHA TRANSMEMBRANE SIGNALING
    COLAMONICI, OR
    DOMANSKI, P
    SWEITZER, SM
    LARNER, A
    BULLER, RML
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (27) : 15974 - 15978
  • [3] Incorporation of the B18R Gene of Vaccinia Virus Into an Oncolytic Herpes Simplex Virus Improves Antitumor Activity
    Fu, Xinping
    Rivera, Armando
    Tao, Lihua
    Zhang, Xiaoliu
    MOLECULAR THERAPY, 2012, 20 (10) : 1871 - 1881
  • [4] Molecular comparison of soluble human interferon-γ receptor and vaccinia virus B8R protein
    Dengler, U
    Kresin, M
    Waschütza, G
    Otto, B
    EUROPEAN CYTOKINE NETWORK, 1998, 9 (03) : 441 - 441
  • [5] Human interferon-ε and interferon-κ exhibit low potency and low affinity for cell-surface IFNAR and the poxvirus antagonist B18R
    Harris, Bethany D.
    Schreiter, Jessica
    Chevrier, Marc
    Jordan, Jarrat L.
    Walter, Mark R.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2018, 293 (41) : 16057 - 16068
  • [6] The Recombinant Vaccinia Virus Gene Product, B18R, Neutralizes Interferon Alpha and Alleviates Histopathological Complications in an HIV Encephalitis Mouse Model
    Fritz-French, Cari
    Shawahna, Ramzi
    Ward, Jennifer E.
    Maroun, Leonard E.
    Tyor, William R.
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2014, 34 (07): : 510 - 517
  • [7] Alteration of immunoregulatory genes expression in mesenchymal stromal cells upon priming with B18R as an interferon binding protein
    Bidkhori, Hamid Reza
    Farshchian, Moein
    Noughabi, Mahboubeh Kazemi
    Hassanzadeh, Halimeh
    Rafatpanah, Houshang
    IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2023, 26 (02) : 241 - 247
  • [8] Recombinant Vaccinia virus-coded interferon inhibitor B18R: Expression, refolding and a use in a mammalian expression system with a RNA-vector
    Kim, Yuriy G.
    Baltabekova, Aliya Zh.
    Zhiyenbay, Erzhan E.
    Aksambayeva, Altynai S.
    Shagyrova, Zhadyra S.
    Khannanov, Rinat
    Ramanculov, Erlan M.
    Shustov, Alexandr V.
    PLOS ONE, 2017, 12 (12):
  • [9] An interferon-γ-binding protein of novel structure encoded by the fowlpox virus
    Puehler, F
    Schwarz, H
    Waidner, B
    Kalinowski, J
    Kaspers, B
    Bereswill, S
    Staeheli, P
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (09) : 6905 - 6911
  • [10] Vaccinia Virus Protein B18R: Influence on mRNA Immunogenicity and Translation upon Non-Viral Delivery in Different Ocular Cell Types
    Minnaert, An-Katrien
    Devoldere, Joke
    Peynshaert, Karen
    Vercruysse, Laure
    De Smedt, Stefaan C.
    Remaut, Katrien
    PHARMACEUTICS, 2021, 13 (01) : 1 - 18